Skip to main content

Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium

Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry population The company is finalizing the development plan for the optimal regulatory pathway to approvalAllschwil, Switzerland – January 30, 2026Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium™, taking place from February 2-6, 2026. The following two posters will be presented on February 5, 15:30 PST (February 6, 00:30 CET):Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study (#125, Kiosk 14-B) Lucerastat effect on kidney function in patients with...

Continue reading

Signify reports full-year 2025 sales of EUR 5.8 billion, operational profitability of 8.9% and a free cash flow of EUR 440 million

Press Release January 30, 2026 Signify reports full-year 2025 sales of EUR 5.8 billion, operational profitability of 8.9% and a free cash flow of EUR 440 million Highlights 1Signify’s installed base of connected light points increased to 167 million at the end of 2025 FY 25 sales of EUR 5,765 million with a CSG of -3.4%; Q4 25 sales of EUR 1,492 million with a CSG of -5.2% Adj. EBITA margin of 8.9% in FY 25 (FY 24: 9.9%) and 10% in Q4 25 (Q4 24: 12.4%) Net income of EUR 259 million (FY 24: EUR 334 million) and EUR 60 million in Q4 25 (Q4 24: 119 million) Free cash flow of EUR 440 million (FY 24: EUR 438 million) and of EUR 291 million in Q4 25 (Q4 24: 188 million) driven by disciplined working capital management Repurchased shares for a total consideration of EUR 150 million; 5.8 million shares cancelled Proposal for cash dividend...

Continue reading

MAISONS DU MONDE: Q4 25 AND FY25 SALES

PRESS RELEASENANTES, JANUARY 30TH, 2026Q4 25 and FY25 sales update H2 Sales stabilization (-0.7% LfL) following -9% in H1Q4 LfL Sales at -5% driven by online underperformance€45m Costs Saving Plan achieved with new €30m ambition for 2026    International and Retail confirm resilience Southern Europe at (-1%) in Q4, with LfL Stores +1% (second positive quarter) Total Retail sales resisted (-2%) LfL of which (-4%) for France Refurbished Stores continue to deliver mid single digit growth  Online facing challengesOnline activities at (-10%), despite record Black Friday campaign, impacted mainly by France and Northern countries  Organization adjusted to focus on digital experience improvement with arrival of new head of digital early January  Cost & Cash 2025 cost saving plan achieved: €45m Positive Cash generation in H2 but...

Continue reading

December 2025 Quarterly Activities Report

QUEBEC CITY, Jan. 30, 2026 (GLOBE NEWSWIRE) — West African gold producer and developer Robex Resources Inc. (“Robex” or the “Company”) (TSX-V: RBX | ASX: RXR | OTC: RSRBF | Börse Frankfurt: RB4) is pleased to report on its activities for the December 2025 quarter. Robex owns and operates the Nampala Gold Mine in Mali and continues to advance the Kiniero Gold Project in Guinea. During the quarter, the Company achieved a major milestone with the first gold pour at Kiniero, marking a significant step toward becoming a multi-asset gold producer in West Africa. Highlights:Shareholder approval secured for Robex’s proposed merger with Predictive Discovery Limited (ASX: PDI), with 94.54% of votes cast in favour at a Special Meeting. This satisfies a key condition and advances the transaction toward completion in Q1 2026. First gold pour...

Continue reading

Vaxcyte Announces Pricing of $550 Million Public Offering

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The offering is expected to close on February 2,...

Continue reading

Anfield Energy Amends Credit Facility with Extract

VANCOUVER, British Columbia, Jan. 29, 2026 (GLOBE NEWSWIRE) — Anfield Energy Inc. (“Anfield” or the “Company”) (TSX.V: AEC; NASDAQ: AEC; FRANKFURT: 0AD) announces that it has entered into an amending and consent agreement (the “Amending Agreement”) with Extract Advisors LLC (“Extract”) to amend the terms of an existing credit facility (the “Credit Facility”) (see the Company’s news release dated October 6, 2023, April 17, 2024 and March 18, 2025) with Extract, as agent of the Credit Facility. Pursuant to the Amending Agreement, Extract consented to the Company’s proposed acquisition (the “Acquisition”) of all of the issued and outstanding securities of B.R.S. Inc. (see the Company’s news release dated December 18, 2025) (the “Consent”). In consideration for the Consent, the Company has agreed to issue 50,000 bonus common shares...

Continue reading

Bombardier Statement

MONTREAL, Jan. 29, 2026 (GLOBE NEWSWIRE) — We have taken note of the post from the President of the United States to social media and are in contact with the Canadian government. Bombardier is an international company that employs more than 3,000 people in the U.S. across 9 major facilities, and creates thousands of U.S. jobs through 2,800 suppliers. Our aircraft, facilities and technicians are fully certified to FAA standards and renowned around the world. We are actively investing in expanding our U.S. operations, including a recent announcement in Fort Wayne, Indiana. Thousands of private and civilian jets built in Canada fly in the U.S. every day. We hope this is quickly resolved to avoid a significant impact to air traffic and the flying public. About Bombardier  At Bombardier (BBD-B.TO), we design, build, modify and maintain...

Continue reading

Mission Success: Rocket Lab Launches Korean Earth-Imaging Satellite, Completes 2nd Launch in 8 Days

LONG BEACH, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched its 81st Electron rocket and second launch in eight days to deploy a satellite for an Earth-observation constellation by the Korea Advanced Institute of Science and Technology (KAIST), Korea’s leading university dedicated to science and technology. ‘Bridging The Swarm’ lifted off on January 30th at 2:21 p.m. NZDT (01:21 UTC) from Rocket Lab’s private orbital launch site, Launch Complex 1 in New Zealand, to deploy the NEONSAT-1A satellite to a 540 km low Earth orbit. NEONSAT-1A is an advanced Earth observation satellite that will test the capabilities of the South Korean government’s future constellation of NEONSAT satellites...

Continue reading

Kyivstar Group Ltd. Announces Pricing of Secondary Offering of Common Shares

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) — Kyivstar Group Ltd. (Nasdaq: KYIV; KYIVW) (“Kyivstar” or the “Company”), Ukraine’s leading digital operator, today announced the pricing of the public offering of 12,500,000 common shares (the “Offering”) by VEON Amsterdam B.V., the principal shareholder of the Company, and certain other selling shareholders (collectively, the “Selling Shareholders”) at a public offering price of USD 10.50 per share. The Company is not selling any common shares in the Offering. In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on February 2, 2026, subject to customary closing conditions. Morgan...

Continue reading

Kyivstar Announces Pricing of Secondary Offering of Common Shares Held by VEON

NEW YORK, New York, January 29, 2026 — VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or, together with its subsidiaries, the “VEON Group”) notes that Kyivstar Group Ltd. (Nasdaq: KYIV; KYIVW) (“Kyivstar” or the “Company”), Ukraine’s leading digital operator, today announced the pricing of the public offering of 12,100,000 common shares held by VEON Amsterdam B.V., the principal shareholder of the Company, and 400,000 common shares held by certain other selling shareholders (collectively, the “Selling Shareholders”) at a public offering price of USD 10.50 per share (the “Offering”). In connection with the Offering, the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the public offering price, less underwriting discounts and commissions. Kyivstar...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.